B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...
Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...
8h
Zacks.com on MSNVaccine Stocks Rise as Chinese Scientists Discover a New CoronavirusStocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%.
Unusual total active option classes on open include: Opko Health ( OPK ), Chewy ( CHWY ), Mini SPX (.XSP), EFA (EFA), Novavax ( NVAX ), B Riley Financial ( RILY ), Pinduoduo ( PDD ), Lucid Group ( ...
Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.
Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...
Shares of Novavax Inc. NVAX slipped 1.25% to $7.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.47% to 19,962.
The stock's fall snapped a three-day winning streak.
Virologists warn the pathogen should be monitored ‘very, very carefully’ because it attacks human cells in the same way as ...
Chinese technology stocks slumped as the country’s economy worsened. That changed when U.S. tariffs against China fell to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results